CA-NETAPP
28.8.2024 22:16:33 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the original intelligent data infrastructure company, today announced new capabilities that support VMware Cloud Foundation deployments. Mutual customers will be able to leverage NetApp solutions to right-size their IT environments to run VMware workloads at scale efficiently.
For more than a decade, NetApp and VMware, recently acquired by Broadcom Inc., have collaborated to ensure the success of their joint customers and help them unlock the full value of their VMware investments. During that time, NetApp has been a key engineering design partner with VMware and is continuing to drive innovation in highly available, scalable and performant storage as a design partner for its Next-Generation vSphere Virtual Volumes (vVols). Now, NetApp is announcing new capabilities that will enable joint customers to run their VMware deployments more efficiently.
“NetApp and Broadcom are working together to take the uncertainty out of hybrid cloud environments,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “More than 20,000 customers rely on NetApp to support their VMware workloads. NetApp's continued close collaboration with Broadcom following the acquisition of VMware ensures our solutions seamlessly interoperate so our mutual customers can leverage a single intelligent data infrastructure to operate their VMware workloads more efficiently.”
NetApp is helping optimize costs, simplify operations, and increase flexibility for customers running VMware environments by offering:
- Expanded Support for VMware Cloud Foundation (VCF): NetApp and Broadcom customers will now be able to simplify their VCF hybrid cloud environments by using NetApp ONTAP® software for all storage requirements, including standard and consolidated architectures. The latest release of ONTAP Tools for VMware (OTV) will support SnapMirror® active sync to provide symmetric active-active data replication capabilities for NetApp storage systems running VMware workloads. SnapMirror active sync allows customers to operate more efficiently by offloading data protection from their virtualized compute and improving data availability.
- New Capabilities for Azure VMware Solution (AVS): To support customers that are extending or migrating their vSphere workloads to the cloud, customers can now leverage Spot Eco by NetApp with AVS reserved instances to get the most value out of their deployments. Using Spot Eco to manage AVS reserved instances while also using Azure NetApp Files to offload data storage can reduce compute costs significantly.
- Enhanced VM Optimization Features for NetApp Cloud Insights: NetApp is introducing Cloud Insights VM Optimization, expanding its comprehensive solution for optimizing virtual environments, including VMware. Cloud Insights VM Optimization will give customers tools to reduce costs by increasing VM density, run storage at the best price-to-performance ratio for their environment, and monitor their entire environment to ensure availability, performance, and adherence to configuration best practices across the entire stack. To help customers optimize the compute, memory and storage resources of their VMware environments, NetApp is also offering customers a free 30-day trial of Cloud Insights to most cost-effectively migrate to the new VMware software subscriptions.
These offerings follow last month’s release of enhancements to NetApp BlueXP™ disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across hybrid cloud environments with newly added support for VMFS datastores.
“As organizations modernize infrastructure with VMware Cloud Foundation, they want to know that the services upon which they rely from industry-leaders such as NetApp will continue to work seamlessly and deliver the value they have come to expect,” said Paul Turner, Vice President of Products, VCF Division at Broadcom. “Having NetApp as a close collaborator helps our mutual customers deploy innovative data and storage services on top of their private cloud platform, and ensure they are getting the most value out of their VMware environments.”
“We have made Microsoft Azure the cloud of choice for VMware environments and offer fast and cost-effective solutions enabling many customers to move their VMware workloads to the cloud,” said Brett Tanzer, Vice President of Product Management at Microsoft. “As VMware customers navigate changes to operating virtualized environments, we have given our customers a way to lock in secure and predictable pricing over multiple years. NetApp's data management and cloud observability capabilities help our customers ensure those deployments are delivering the return on investment they need.”
“In an ever more complicated world of cloud, data, and infrastructure operations, IT teams are increasingly looking for holistic platforms over point solutions,” said Scott Sinclair, Practice Director, Enterprise Strategy Group. “These joint updates from NetApp and Broadcom enable customers to use NetApp’s intelligent data infrastructure to consolidate multiple data operations onto a single platform with industry-leading data management and CloudOps capabilities. That will help customers drive greater operational and infrastructure efficiencies that reduce the total cost of ownership for their VMware investments.”
Additional Resources
About NetApp
NetApp is the original intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828604243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom